Compare LMB & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMB | IVA |
|---|---|---|
| Founded | 1901 | 2011 |
| Country | United States | France |
| Employees | 1400 | 77 |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 960.5M | 883.8M |
| IPO Year | 2014 | N/A |
| Metric | LMB | IVA |
|---|---|---|
| Price | $79.56 | $4.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $116.67 | $16.20 |
| AVG Volume (30 Days) | 323.5K | ★ 466.4K |
| Earning Date | 05-05-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.68 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $646,804,000.00 | N/A |
| Revenue This Year | $15.96 | N/A |
| Revenue Next Year | $5.90 | $751.20 |
| P/E Ratio | $234.25 | ★ N/A |
| Revenue Growth | ★ 24.68 | N/A |
| 52 Week Low | $65.08 | $2.94 |
| 52 Week High | $154.04 | $7.98 |
| Indicator | LMB | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 49.10 | 32.13 |
| Support Level | $76.97 | $3.77 |
| Resistance Level | $85.38 | $4.67 |
| Average True Range (ATR) | 4.91 | 0.32 |
| MACD | 1.16 | -0.12 |
| Stochastic Oscillator | 63.27 | 12.35 |
Limbach Holdings Inc is a building systems solutions firm that designs, delivers, and maintains mechanical (heating, ventilation, and air conditioning), electrical, plumbing, and controls (MEPC) systems. The Company partners with owners and operators of facilities across healthcare, industrial and manufacturing, data centers, life sciences, higher education, and cultural and entertainment markets. It operates through two segments: Owner Direct Relationships (ODR), which generates maximum revenue and includes owner direct projects, maintenance, and service on MEPC systems; and General Contractor Relationships (GCR), which manages new construction or renovation projects involving MEPC systems awarded by general contractors or construction managers.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.